
Lakewood nonprofit that offers older Colorado residents free home repairs sees more and more requests
At a retirement community in Lakewood this week, Bright Leaf volunteer Jenna Melliadis recently was making some new friends, one door knock at a time. She met Dennis Howard, a 77 year old who lives in the neighborhood. Howard spends most of his time outside these days after his longtime wife passed away in the last year. All kinds of things in the house remind him of her, down to the torn up linoleum on his kitchen floor from where her wheeled chairs would wear down the tile. They used to scrape by on two combined Social Security incomes, but after her passing, Howard has had to shoulder the costs of everything alone.
Bright Leaf volunteer Jenna Melliadis chats with Dennis Howard in his home.
CBS
"It's really hard to afford your rent, food and repairs and stuff," he told CBS Colorado. "You have to put them on the back burner."
The floor damage has been on the to do list for awhile, he explained, and he was afraid that one day he would slip on it and fall in his home.
"I couldn't afford to have it done, so thank God these guys came by and are able to help me with it," said Howard.
The knock on the door from Melliadis changed things.
Bright Leaf is primarily volunteer driven outside of Executive Director Steve Olguin and other senior staff that handle scheduling and coordination.
"Being able to provide services that help people survive safely and comfortably in their home is so important," Melliadis said.
CBS Colorado's Andrew Haubner interviews Bright Leaf Executive Director Steve Olguin.
CBS
For her, it hits home in a particularly pronounced way. Her mother passed away three months ago and couldn't spend some of her last days and weeks in the comfort of her home. Every walk into a home is a chance to give these seniors an opportunity to be happy, healthy and cared for.
"Because this is such a personal cause and mission to my heart it is unbelievably gratifying," she said. "The impacts that we're able to have on each individual, knowing that they're happy, that they're comfortable, that they're safe is just such a huge blessing."
Bright Leaf Inc. started out as a Facebook group where people would share resources and a way to help elderly individuals like grandparents or other family members. Over the next few years, more calls for service would come and Olguin decided to put his experience as a roofer and contractor to work. The group did receive grant funding but recent administrative changes within state and federal governments have forced them to look into other funding avenues. Nowadays, Olguin says, they operate primarily on community donations, volunteer time and good Samaritans that are willing to lend a hand, a lawn mower, or a power drill to help those in need.
Since 2022, Olguin said, calls have been more frequent and tips regularly come in regarding neighborhoods and people to help. But 2025 has been a particularly intense period of work.
"The beginning of 2025 is a time when we have seen the most requests come in," he said.
Based on those calls and tips, the volunteers will fan out to areas like the Lakewood community they were in this week. Typically, the trips are two days in length. The first is to knock on doors, meet residents and see what they need help with. Olguin and his team divvy up responsibilities, what contractors need to be called and who can do what work and then the next morning, crews are out to fix what needs to be fixed. It can be anything from lawn mowing and weed whacking to bigger projects like replacing carpets or making showers ADA compliant for residents that are now using walking aids.
CBS
"To be able to help a senior do some repairs on their home that they wouldn't otherwise be able to afford or they don't have family support, it shows them that there are people out there that do care," Olguin said.
"It's a godsend," Dennis said, his eyes beginning to well. "I had no idea that this help was out there. People need to know."
After just one day, Dennis Howard has a friend in Jenna Melliadis. Soon, the rip in his floor will be gone. And Bright Leaf Inc. will be on to the next place, trying to provide some help and comfort to those that need it.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
4 hours ago
- Associated Press
Hurricane Erin weakens to Category 3 as forecasters wait for northward turn
The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world's population sees AP journalism every day.
Yahoo
4 hours ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool


Associated Press
4 hours ago
- Associated Press
Police and demonstrators clash in Valjevo as tensions soar in Serbia
The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world's population sees AP journalism every day.